Evidence map›Paper›PMID 38505850›Full record

ArticleACS medicinal chemistry letters2024

Novel-Type GABA

Balázs Krámos, Zsuzsa Hadady, Attila Makó, Gábor Szántó, Nóra Felföldi, Ildikó Magdó, Amrita Ágnes Bobok, Imre Bata, Viktor Román, András Visegrády and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Access to Pyrazolo[1,5-Organic letters · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Balázs KrámosSpectroscopic Research Department, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, 1103 Hungary.ORCID https://orcid.org/0000-0002-6387-7382
Zsuzsa HadadyChemistry Department, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, 1103 Hungary.
Attila MakóChemistry Department, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, 1103 Hungary.
Gábor SzántóChemistry Department, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, 1103 Hungary.
Nóra FelföldiChemistry Department, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, 1103 Hungary.
Ildikó MagdóSpectroscopic Research Department, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, 1103 Hungary.
Amrita Ágnes BobokPharmacological and Drug Safety Research, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, 1103 Hungary.
Imre BataChemistry Department, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, 1103 Hungary.
Viktor RománPharmacological and Drug Safety Research, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, 1103 Hungary.
András VisegrádyPharmacological and Drug Safety Research, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, 1103 Hungary.
György M KeserűMedicinal Chemistry Research Group, Research Centre for Natural Sciences, Magyar tudósok krt. 2, Budapest, 1117 Hungary.
István GreinerResearch and Development Director, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, 1103 Hungary.ORCID https://orcid.org/0000-0002-5336-2828
János ÉlesHead of Medicinal Chemistry, Gedeon Richter Plc., Gyömrői út 19-21, Budapest, 1103 Hungary.ORCID https://orcid.org/0000-0001-9185-1123

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selecting a known HTS hit with the pyrazolo[1,5-

Identifiers

PMID38505850
PMCPMC10945541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.